Brief: Pharnext Announces FDA Fast Track Designation For PLEODRUG(TM) PXT3003
04/02/2019 16:51
Feb 4 (Reuters) - PHARNEXT SA PHARN.PA :
* PHARNEXT: PHARNEXT ANNOUNCES FDA FAST TRACK DESIGNATION
FOR
PLEODRUG(TM) PXT3003 FOR THE TREATMENT OF CHARCOT-MARIE-TOOTH
DISEASE TYPE 1A
Source text for Eikon: ID:nEQ8jmQCPa
Further company coverage: PHARN.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))
Recent news on Pharnext SCA
See all newsBrief: Pharnext Progresses On Charcot-Marie-Tooth Disease Study
Brief: Pharnext Reports Topline Results From Pivotal Phase III Clinical Trial Of PXT3003 In Charcot-Marie-Tooth Disease Type 1A
Brief: Pharnext Receives Offer Valuing Its Drug Candidate For Charcotmarie-Tooth Disease At Over Eur 500 Mln
Brief: Pharnext Appoints Dr Gilbert Wagener As Chief Medical Officer
Brief: Pharnext Reports Significant Progress In Search For Pharmaceutical Partners To Finance Its Development